Zymeworks Inc. effective March 31, 2024 (the Separation Date), Zymeworks Inc. (the Company) removed Dr. Christopher Astle from the positions of Senior Vice President, including as the Company?s principal financial officer and principal accounting officer. Over the last two years in his position as Senior Vice President and Chief Financial Officer, Dr. Astle helped with the reset of the Company and to put the Company in a strong financial position, and the Company thanks him for his service.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.605 USD | +0.29% | +0.23% | -17.42% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.42% | 605M | |
-3.46% | 102B | |
+1.41% | 96.09B | |
+2.13% | 22.28B | |
-15.84% | 21.4B | |
-9.28% | 18.14B | |
-39.98% | 17.02B | |
-14.65% | 16.09B | |
+4.39% | 13.83B | |
+31.35% | 11.97B |
- Stock Market
- Equities
- ZYME Stock
- News Zymeworks Inc.
- Zymeworks Inc. Removes Dr. Christopher Astle from the Positions of Senior Vice President